Clinicopathological significance of expression of paxillin, syndecan-1 and EMMPRIN in hepatocellular carcinoma

World Journal of Gastroenterology

Volumn 11, Issue 10, 2005, Pages 1445-1451

  Li, Hai Gang ^a   Xie, De Rong ^a   Shen, Xi Ming ^a   Li, Hong Hao ^a   Zeng, Hong ^a   Zeng, Yun Jie ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

EMMPRIN; Hepatocellular carcinoma; Immunohistochemistry; Paxillin; Syndecan 1

Indexed keywords

ALPHA FETOPROTEIN; CD147 ANTIGEN; HEPATITIS B SURFACE ANTIGEN; PAXILLIN; SYNDECAN 1;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; PORTAL VEIN THROMBOSIS; PROGNOSIS; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TUMOR DIFFERENTIATION; TUMOR VOLUME;

EID: 16344388747     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i10.1445     Document Type: Article

References (45)

1. Srivatanakul P, Sriplung H, Deerasamee S. Epidemiology of liver cancer: An overview. Asian Pac J Cancer Prev 2004; 5 118-125
2. Yu AS, Keeffe EB. Management of hepatocellular carcinoma. Rev Gastroenterol Disord 2003; 3: 8-24
3. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-750
4. Kiyosawa K, Tanaka E. Characteristics of hepatocellular carcinoma in Japan. Oncology 2002; 62(Suppl 1): 5-7
5. Tang ZY. Hepatocellular carcinoma-cause, treatment and metastasis. World J Gastroenterol 2001; 7: 445-454
6. Zhang S, Li L, Lu F. Mortality of primary liver cancer in China from 1990 through 1992. Zhonghua Zhongliu Zazhi 1999; 21: 245-249
7. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999; 83: 18-29
8. Johnson PJ. Hepatocellular carcinoma: Is current therapy really altering outcome? Gut 2002; 51: 459-462
9. Watanabe T, Omori M, Fukuda H, Takada H, Miyao M, Mizuno Y, Ohsawa I, Sato Y, Hasegawa T. Analysis of sex, age and disease factors contributing to prolonged life expectancy at birth, in cases of malignant neoplasms in Japan. J Epidemiol 2003; 13: 169-175
10. Ziparo V, Balducci G, Lucandri G, Mercantini P, Di Giacomo G, Fernandes E. Indications and results of resection for hepatocellular carcinoma. Eur J Surg Oncol 2002; 28: 723-728
11. Kanematsu T, Furui J, Yanaga K, Okudaira S, Shimada M, Shirabe K. A 16-year experience in performing hepatic resection in 303 patients with hepatocellular carcinoma: 1985-2000. Surgery 2002; 131(1 Suppl): S153-158
12. Aguayo A, Patt YZ. Liver cancer. Clin Liver Dis 2001; 5: 479-507
13. Yano H, Mazaki Y, Kurokawa K, Hanks SK, Matsuda M, Sabe H. Roles played by a subset of integrin signaling molecules in cadherin-based cell-cell adhesion. J Cell Biol 2004; 166: 283-295
14. Romanova LY, Hashimoto S, Chay KO, Blagosklonny MV, Sabe H, Mushinski JF. Phosphorylation of paxillin tyrosines 31 and 118 controls polarization and motility of lymphoid cells and is PMA-sensitive. J Cell Sci 2004; 117(Pt 17): 3759-3768
15. Sattler M, Pisick E, Morrison PT, Salgia R. Role of the cytoskeletal protein paxillin in oncogenesis. Crit Rev Oncog 2000; 11: 63-76
16. Turner CE. Paxillin interactions. J Cell Sci 2000; 113(Pt 23): 4139-4140
17. Della Morte R, Squillacioti C, Garbi C, Derkinderen P, Belisario MA, Girault JA, Di Natale P, Nitsch L, Staiano N. Echistatin inhibits pp125FAK autophosphorylation, paxillin phosphorylation and pp125FAK-paxillin interaction in fibronectin-adherent melanoma cells. Eur J Biochem 2000; 267: 5047-5054
18. Roskams T, De Vos R, David G, Van Damme B, Desmet V. Heparan sulphate proteoglycan expression in human primary liver tumors. J Pathol 1998; 185: 290-297
19. Kiviniemi J, Kallajoki M, Kujala I, Matikainen MT, Alanen K, Jalkanen M, Salmivirta M. Altered expression of syndecan-1 in prostate cancer. APMIS 2004; 112: 89-97
20. Muramatsu T, Miyauchi T. Basigin (CD147): A multifunctional transmembrane protein involved in reproduction, neural function, inflammation and tumor invasion. Histol Histopathol 2003; 18: 981-987
21. Marieb EA, Zoltan-Jones A, Li R, Misra S, Ghatak S, Cao J, Zucker S, Toole BP. Emmprin promotes anchorage-independent growth in human mammary carcinoma cells by stimulating hyaluronan production. Cancer Res 2004; 64: 1229-1232
22. Dalberg K, Eriksson E, Enberg U, Kjellman M, Backdahl M. Gelatinase A, membrane type 1 matrix metalloproteinase, and extracellular matrix metalloproteinase inducer mRNA expression: Correlation with invasive growth of breast cancer. World J Surg 2000; 24: 334-340
23. Sun J, Hemler ME. Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase inducer interactions. Cancer Res 2001; 61: 2276-2281
24. Hefler LA, Concin N, Mincham D, Thompson J, Swarte NB, von Eijkeren MA, Sie-Go DM, Hammond I, McCartney AJ, Tempfer CB, Speiser P. The prognostic value of immunohistochemically detected CD44v3 and CD44v6 expression in patients with surgically staged vulvar carcinoma: A multicenter study. Cancer 2002; 94: 125-130
25. Wei QY, Wu YQ, Fan SQ. Expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the hepatocellular carcinomas. Hunan Yike Daxue Xuebao 2003; 28 212-216
26. Ohtake T, Fujimoto Y, Ikuta K, Saito H, Ohhira M, Ono M, Kohgo Y. Proline-rich antimicrobial peptide, PR-39 gene transduction altered invasive activity and actin structure in human hepatocellular carcinoma cells. Br J Cancer 1999; 81: 393-403
27. Leyton J, Garcia-Marin LJ, Tapia JA, Jensen RT, Moody TW. Bombesin and gastrin releasing peptide increase tyrosine phosphorylation of focal adhesion kinase and paxillin in non-small cell lung cancer cells. Cancer Lett 2001; 162: 87-95
28. Mennerich D, Vogel A, Klaman I, Dahl E, Lichtner RB, Rosenthal A, Pohlenz HD, Thierauch KH, Sommer A. Shift of syndecan-1 expression from epithelial to stromal cells during progression of solid tumors. Eur J Cancer 2004; 40: 1373-1382
29. Han JL, Xie WL, Huang J, Yao YS. Expression of extracellular matrix metalloproteinase inducer in human bladder transitional cell carcinoma. Aizheng 2003; 22: 1158-1161
30. Yano H, Uchida H, Iwasaki T, Mukai M, Akedo H, Nakamura K, Hashimoto S, Sabe H. Paxillin alpha and Crk-associated substrate exert opposing effects on cell migration and contact inhibition of growth through tyrosine phosphorylation. Proc Natl Acad Sci USA 2000; 97: 9076-9081
31. Yu CF, Sanders MA, Basson MD. Human caco-2 motility redistributes FAK and paxillin and activates p38 MAPK in a matrix-dependent manner. Am J Physiol Gastointest Liver Physiol 2000; 278: G952-G966
32. Umino T, Wang H, Zhu Y, Liu X, Manouilova LS, Spurzem JR, Patricia Leuschen M, Rennard SI. Modification of type I collagenous gels by alveolar epithelial cells. Am J Respir Cell Mol Biol 2000; 22: 702-707
33. Imamura F, Mukai M, Ayaki M, Akedo H. Y-27632, an inhibitor of rho-associated protein kinase, suppresses tumor cell invasion via regulation of focal adhesion and focal adhesion kinase. Jpn J Cancer Res 2000; 91: 811-816
34. Tu LC, Chou CK, Chen HC, Yeh SF. Protein kinase C-mediated tyrosine phosphorylation of paxillin and focal adhesion kinase requires cytoskeletal integrity and is uncoupled to mitogen-activated protein kinase activation in human hepatoma cells. J Biomed Sci 2001; 8: 184-190
35. Yoon WH, Song IS, Lee BH, Jung YJ, Kim TD, Li G, Lee TG, Park HD, Lim K, Hwang BD. Differential regulation of vimentin mRNA by 12-O-tetradecanoylphorbol 13-acetate and all-trans-retinoic acid correlates with motility of Hep 3B human hepatocellular carcinoma cells. Cancer Lett 2004; 203: 99-105
36. Watari J, Saitoh Y, Fujiya M, Shibata N, Tanabe H, Inaba Y, Okamoto K, Maemoto A, Ohta T, Yasuda A, Ayabe T, Ashida T, Yokota K, Obara T, Kohgo Y. Reduction of syndecan-1 expression in differentiated type early gastric cancer and background mucosa with gastric cellular phenotype. J Gastroenterol 2004; 39: 104-112
37. Matsumoto A, Ono M, Fujimoto Y, Gallo RL, Bernfield M, Kohgo Y. Reduced expression of syndecan-1 in human hepatocellular carcinoma with high metastatic potential. Int J Cancer 1997; 74 482-491
38. Freije JM, Balbin M, Pendas AM, Sanchez LM, Puente XS, Lopez-Otin C. Matrix metalloproteinases and tumor progression. Adv Exp Med Biol 2003; 532: 91-107
39. Tutton MG, George ML, Eccles SA, Burton S, Swift RI, Abulafi AM. Use of plasma MMP-2 and MMP-9 levels as a surrogate for tumour expression in colorectal cancer patients. Int J Cancer 2003; 107: 541-550
40. Lee SJ, Sakurai H, Oshima K, Kim SH, Saiki I. Anti-metastatic and anti-angiogenic activities of a new matrix metalloproteinase inhibitor, TN-6b. Eur J Cancer 2003; 39: 1632-1641
41. London CA, Sekhon HS, Arora V, Stein DA, Iversen PL, Devi GR. A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity. Cancer Gene Ther 2003; 10: 823-832
42. Gakiopoulou H, Nakopoulou L, Siatelis A, Mavrommatis I, Panayotopoulou EG, Tsirmpa I, Stravodimos C, Giannopoulos A. Tissue inhibitor of metalloproteinase-2 as a multifunctional molecule of which the expression is associated with adverse prognosis of patients with urothelial bladder carcinomas. Clin Cancer Res 2003; 9: 5573-5581
43. Ishii Y, Nakasato Y, Kobayashi S, Yamazaki Y, Aoki T. A study on angiogenesis-related matrix metalloproteinase networks in primary hepatocellular carcinoma. J Exp Clin Cancer Res 2003; 22 461-470
44. Harvey SR, Hurd TC, Markus G, Martinick MI, Penetrante RM, Tan D, Venkataraman P, DeSouza N, Sait SN, Driscoll DL, Gibbs JF. Evaluation of urinary plasminogen activator, its receptor, matrix metalloproteinase-9, and von Willebrand factor in pancreatic cancer. Clin Cancer Res 2003; 9: 4935-4943
45. Thorns V, Walter GF, Thorns C. Expression of MMP-2, MMP-7, MMP-9, MMP-10 and MMP-11 in human astrocytic and oligodendroglial gliomas. Anticancer Res 2003; 23: 3937-3944